<span item_type="fundamental" item_id="7db6c83c53c7e4e0312b3a22214b8d13" counter_id="ST/US/AMRN" env="prod"></span><span item_type="announcement" item_id="621956257771885953" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 213.65 M, missing the estimate of USD 215.08 M.</p><p>EPS: As of FY2025, the actual value is USD -0.09.</p><p>EBIT: As of FY2025, the actual value is USD -61.03 M.</p><p></p><p>Amarin Corporation plc operates in one business segment, and its financial and operational metrics are as follows:</p><h4>Net Losses and Accumulated Deficit</h4><ul><li>阿玛琳 reported net losses of - $38.8 million for the fiscal year ended December 31, 2025, - $82.2 million for 2024, and - $59.1 million for 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>The company had an accumulated deficit of $1.7 billion as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Total Revenue, Net</h4><ul><li>Total revenue, net, was $213.6 million for the year ended December 31, 2025, representing a decrease of $15.0 million, or 7%, from $228.6 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>This decrease was driven by reductions of - $12.6 million in U.S. net product revenue and - $9.3 million in net product revenue from sales of VASCEPA to partners outside the U.S., partially offset by an increase of $6.9 million in licensing and royalty revenue.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Product Revenue, Net</h4><ul><li>Product revenue, net, was $182.8 million for the year ended December 31, 2025, a decrease of $21.8 million, or 11%, from $204.6 million in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span><ul><li><strong>U.S. Product Revenue, Net</strong>: $154.1 million for 2025, down from $166.7 million for 2024, primarily due to a decline in net selling price from generic competition.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Europe Product Revenue, Net</strong>: $18.4 million for 2025, up from $13.7 million for 2024, mainly from the UK and Spain.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Rest of World (RoW) Product Revenue, Net</strong>: $10.2 million for 2025, down from $24.2 million for 2024, reflecting normal variability in early-stage ex-U.S. market development.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul></li></ul><h4>Licensing and Royalty Revenue</h4><ul><li>Licensing and royalty revenue was $30.9 million for 2025, an increase of $6.9 million, or 29%, from $24.0 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>This increase was primarily due to a $25.0 million upfront payment from the Recordati Licensing Agreement and higher royalties from increased partner sales.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>In 2024, $15.0 million in milestone payments and a $4.0 million change in estimate were recognized due to the regulatory approval of VASCEPA under the REDUCE-IT indication in China.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Cost of Goods Sold</h4><ul><li>Cost of goods sold was $92.8 million for 2025, a decrease of $54.5 million, or 37%, from $147.2 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>In 2024, a $36.5 million charge was recorded as cost of goods sold - restructuring inventory related to amending supplier agreements.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>In 2025, approximately $0.4 million of inventory was expensed due to product dating, compared to approximately $8.0 million in 2024 due to product dating and non-product dating unsellable inventory.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Gross Margin</h4><ul><li>Overall gross margin on product sales was 49% for 2025 and 28% for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li>Excluding restructuring inventory and inventory write-off charges, gross margin was 49% for 2025 and 50% for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Selling, General and Administrative Expense (SG&amp;A)</h4><ul><li>SG&amp;A expense was $115.0 million for 2025, a decrease of $37.3 million, or 24%, from $152.3 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span><ul><li><strong>Selling expense</strong>: $40.6 million for 2025, a decrease of $39.0 million, or 49%, from $79.6 million for 2024, mainly due to reductions from the Global Restructuring Plan and other cost optimization initiatives.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>General and administrative expenses</strong>: $65.2 million for 2025, an increase of $6.6 million, or 11%, from $58.6 million for 2024, primarily due to fees related to the ADS Ratio Change and Recordati Licensing Agreement, offset by decreased branded pharma fees and Global Restructuring Plan cost reductions.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Non-cash stock-based compensation expense (SG&amp;A)</strong>: $9.2 million for 2025, a decrease of $4.9 million, or 35%, from $14.2 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul></li></ul><h4>Research and Development Expense (R&amp;D)</h4><ul><li>R&amp;D expense was $19.8 million for 2025, a decrease of $1.1 million, or 5%, from $20.9 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Restructuring Expense</h4><ul><li>Restructuring expense was $36.2 million for 2025, an increase of $36.2 million from - $0 million for 2024, attributed to the Global Restructuring Plan related to the Recordati Licensing Agreement.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Interest Income, Net</h4><ul><li>Interest income, net, was $10.8 million for 2025, a decrease of $2.6 million, or 19%, from $13.4 million for 2024, primarily due to lower interest rates.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Other Income, Net</h4><ul><li>Other income, net, was $3.3 million for 2025, up from $1.2 million for 2024, mainly from foreign exchange gains and sublease income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Provision for Income Taxes</h4><ul><li>Provision for income taxes was $2.8 million for 2025, down from $5.0 million for 2024, due to a change in the geographic mix of pre-tax income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Cash Flow Summary</h4><ul><li><strong>Operating Activities</strong>: Cash provided was $6.7 million in 2025, compared to cash used of - $31.0 million in 2024 and cash provided of $6.9 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Investing Activities</strong>: Cash provided was $8.8 million in 2025, compared to cash used of - $46.0 million in 2024 and - $25.5 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Financing Activities</strong>: Cash used was - $2.0 million in 2025, compared to - $1.4 million in 2024 and cash provided of $0.2 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Increase (decrease) in cash and cash equivalents and restricted cash</strong>: An increase of $13.5 million in 2025, following decreases of - $78.4 million in 2024 and - $18.4 million in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Other Key Metrics</h4><ul><li><strong>Icosapent Ethyl Market Share (U.S.)</strong>: 阿玛琳’s share decreased to approximately 47% in 2025 from approximately 53% in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>VASCEPA-branded Prescriptions (U.S.)</strong>: Decreased by 10% in 2025 compared to 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Inventory</strong>: $195.9 million as of December 31, 2025, with approximately 50% approved for use in North America.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Net Accounts Receivable</strong>: $126.8 million as of December 31, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Cash and Investments</strong>: Totaled $302.6 million as of December 31, 2025, comprising $134.7 million in cash and cash equivalents and $167.9 million in short-term investments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li><li><strong>Employees</strong>: Approximately 80 full-time employees located in six countries as of December 31, 2025, with 60% in the U.S. and 40% in Europe.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></li></ul><h4>Outlook / Guidance</h4><p>阿玛琳 expects its Global Restructuring Plan, announced in June 2025, to reduce annual operating costs by approximately $70 million, primarily from eliminating commercial roles in European operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span> The company believes its $302.6 million in cash and investments as of December 31, 2025, will be sufficient to fund projected operations for at least one year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span> While a share repurchase program for up to $50.0 million was approved in 2024, no repurchases have commenced as of the reporting date.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/897448/000119312526085818/amrn-20251231.htm"></span></p>

Amarin | 10-K: FY2025 Revenue Misses Estimate at USD 213.65 M